


TSE : 4568

Reference Data

Consolidated Financial Results for Q2 FY2010



Daiichi-Sankyo

October 29, 2010

Daiichi Sankyo Co., Ltd.
<http://www.daiichisankyo.com>

(This page is intentionally left blank)



Daiichi-Sankyo

Reference Data

Consolidated Financial Results for Q2 FY2010

[1]	Summary of Income Statement	P1
[2]	Currency Rate	P2
[3]	Sales of Global Products	P3
[4]	Overseas Sales	P4
[5]	Geographic Segment Information	P4
[6]	Status of Major Companies	P5
[7]	Number of Employees	P9
[8]	Major Management / Financial Indicators	P10
[9]	Capital Expenditure and Depreciation Expenses	P10
[10]	Number of Shares Held and Shareholders by Category	P10
[11]	Consolidated Balance Sheets	P11
[12]	Consolidated Statements of Cash Flows	P13
[13]	R&D Pipeline	P14

<Historical Data>

Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value.

1. Summary of Income Statement

< Consolidated Income Statement >

(Billions of yen)

	FY2010 Results						Details (YoY Changes)
	Q2		Q2 YTD		From Aug. Forecast	YoY Changes	
Net Sales	<-0.4>		<6.0>				Ranbaxy Group: ¥+32.4 bil Olmesartan: ¥+6.2 bil, Loxonin: ¥+3.2 bil Levofloxacin: ¥-9.4 bil, Pravastatin: ¥-6.0 bil [Decrease by yen appreciation: Approx. ¥-14.0 bil]
	100.0	242.5	100.0	498.9	3.9	28.3	
Cost of Sales	30.7	74.4	27.8	138.5	-0.5	1.2	Cost to sales ratio: -1.4 Points (Impact of Ranbaxy: -1.5 Points)
SG&A Expenses	57.3	139.0	54.2	270.3	-15.7	-12.2	Decrease by yen appreciation: Approx. ¥-10.5 bil
R&D Expenses	18.9	45.7	17.9	89.3	-7.7	-4.8	
Other Expenses	38.5	93.3	36.3	181.0	-8.0	-7.4	
Operating Income	<20.6>		<77.2>				
	12.0	29.0	18.1	90.1	20.1	39.3	
Non-operating Income		-1.7		10.1		-4.7	Gain on valuation of Ranbaxy's forex derivatives, etc.
Non-operating Expenses		4.8		7.6		-5.8	Foreign exchange losses of Ranbaxy, etc.
Ordinary Income	<-50.0>		<77.3>				
	9.3	22.6	18.6	92.6	22.6	40.4	
Extraordinary Gains		6.8		7.6		5.2	Gain on sales of non-current assets, etc.
Extraordinary Losses		1.3		6.1		5.1	Loss on valuation of investment securities, etc.
Income before taxes and minority interests	11.6	28.0	18.9	94.1		40.5	
Income Taxes		8.2		34.7		-2.0	Tax rate: 36.9%
Minority Interests		0.8		7.3		9.0	
Net Income	<-24.1>		<179.0>				
	7.9	19.1	10.5	52.2	19.2	33.5	

< Daiichi Sankyo Group >

	FY2010 Results		
	Q2 YTD		YoY Changes
Net Sales	<-1.0>		
	100.0	400.4	-4.0
Cost of Sales	24.8	99.3	-0.4
SG&A Expenses	58.6	234.7	-13.8
R&D Expenses	20.9	83.8	-5.9
Other Expenses	37.7	150.9	-7.9
Operating Income	<18.1>		
	16.6	66.4	10.2
Non-operating Income		3.7	-1.2
Non-operating Expenses		3.7	1.2
Ordinary Income	<13.4>		
	16.6	66.4	7.9
Extraordinary Gains		4.6	2.3
Extraordinary Losses		5.2	4.2
Income before taxes and minority interests	16.4	65.8	5.9
Income Taxes		25.2	-11.6
Minority Interests			
Net Income	<75.4>		
	10.2	40.6	17.5

< Ranbaxy Group >

	FY2010 Results		
	Q2 YTD (Jan-Jun)*		YoY Changes
Net Sales	<49.2>		
	100.0	98.7	32.5
Cost of Sales	39.8	39.2	1.7
SG&A Expenses	33.9	33.5	2.5
R&D Expenses	6.4	6.4	1.9
Other Expenses	27.5	27.1	0.6
Operating Income	<->		
	26.3	25.9	28.3
Non-operating Income		7.0	-2.9
Non-operating Expenses		3.8	-7.1
Ordinary Income	<->		
	29.6	29.2	32.5
Extraordinary Gains		5.2	5.1
Extraordinary Losses		0.7	0.7
Income before taxes and minority interests	34.1	33.7	36.9
Income Taxes		10.7	11.3
Minority Interests		0.1	0.0
Net Income	<->		
	23.2	22.9	25.6

< Inter-Segment Transactions >

	FY2010 Results	
	Q2 YTD	YoY Changes
Net Sales	-0.2	-0.2
Cost of Sales	0.0	0.0
SG&A Expenses	2.1	-0.9
R&D Expenses	-0.9	-0.9
Other Expenses	3.0	0.0
Operating Income	-2.3	0.7
Non-operating Income	-0.7	-0.7
Non-operating Expenses	0.1	0.1
Ordinary Income	-3.0	0.0
Extraordinary Gains	-2.2	-2.2
Extraordinary Losses	0.2	0.2
Income before taxes and minority interests	-5.4	-2.4
Income Taxes	-1.2	-1.8
Minority Interests	7.1	9.0
Net Income	-11.4	-9.6

* Due to the difference in fiscal year-end, Ranbaxy's results included in the Group's Q2 YTD FY2010 are those of Jan-Jun 2010.

(Billions of yen)

	FY2010 Forecast						Details (From Aug. Forecast)
	2nd half		Full Year		YoY Changes	From Aug. Forecast	
Net Sales	<-0.1>		<2.9>				[Positive Factors: ¥+18.0 bil] Increased sales of Ranbaxy, Luitpold, and others [Negative Factors: ¥-18.0 bil] Forex impact
	100.0	481.1	100.0	980.0	27.9	0.0	
Cost of Sales	31.9	153.5	29.8	292.0	14.0	2.0	Increased costs from higher sales: ¥+4.0 bil Forex impact: ¥-2.0 bil
SG&A Expenses	66.0	317.7	60.0	588.0	9.4	-12.0	
R&D Expenses	25.1	120.7	21.4	210.0	13.2	0.0	Forex impact: ¥-5.0 bil Cost containment, etc.: ¥-3.0 bil
Other Expenses	41.0	197.0	38.6	378.0	-3.8	-12.0	Forex impact: ¥-9.0 bil Cost containment: ¥-3.0 bil
Operating Income	<-77.8>		<4.7>				
	2.1	9.9	10.2	100.0	4.5	10.0	
Non-operating Income / (Expenses)		-2.5		0.0	-7.6	5.0	
Ordinary Income	<-85.5>		<-3.0>				
	1.5	7.4	10.2	100.0	-3.1	15.0	
Extraordinary Gains / (Losses)		0.5		2.0	7.7	2.0	
Income before taxes and minority interests	1.6	7.9	10.4	102.0	4.6	17.0	
Income Taxes / Minority Interests		5.0		47.0	-8.5	7.0	
Net Income	<-87.8>		<31.4>				
	0.6	2.8	5.6	55.0	13.1	10.0	

2. Currency Rate

	FY2009	FY2010			FY2010 Original Full Year Forecast
	Q2 YTD Results	Q2 YTD Results	Full Year Forecast	Annual impact of one yen change in currency rate	
USD / Yen (average)	95.5	89.0	85.0	Net Sales ¥2.5 billion Operating Income ¥0.2 billion	90.0
EUR / Yen (average)	133.2	113.8	111.9	Net Sales ¥0.7 billion Operating Income ¥0.1 billion	120.0

* We do not revise forecasts by company and product line.

3. Sales of Global Products

	FY2010 Results				(Billions of yen)	
	Q2	Q2 YTD	Progress	YoY Changes	FY2010 Forecast *	
					Full Year	YoY Changes
Olmesartan <antihypertensive>	<3.4> 61.4	<5.4> 121.6	46.8%	6.2	<9.1> 260.0	21.7
Olmetec (JPN)	<6.5> 21.1	<7.6> 41.8	48.6%	2.9	<11.4> 86.0	8.8
Rezaltas (JPN)	<-> 0.1	<-> 1.9	37.7%	1.9	<-> 5.0	5.0
Benicar HCT / Benicar (US)	<-6.8> 20.7	<-4.9> 42.1	47.1%	-2.2	<0.6> 89.5	0.6
Azor (US)	<6.8> 3.4	<16.1> 7.2	55.3%	1.0	<1.7> 13.0	0.2
Tribenzor (US)	<-> 0.7	<-> 0.7	-	0.7	-	-
Olmetec Plus / Olmetec (EU)	<-6.7> 9.3	<-5.6> 17.2	42.0%	-1.0	<2.7> 41.0	1.1
Sevikar (EU)	<97.4> 2.4	<92.0> 4.0	42.6%	1.9	<50.0> 9.5	3.2
Other subsidiaries / Export, etc.	<25.4> 3.9	<17.3> 6.7	41.9%	1.0	<21.8> 16.0	2.9
Levofloxacin <synthetic antibacterial>	<-28.0> 16.9	<-21.7> 33.9	48.4%	-9.4	<-19.7> 70.0	-17.2
Cravit (JPN)	<-36.7> 7.5	<-28.5> 15.3	46.4%	-6.1	<-24.4> 33.0	-10.6
Export, etc	<-29.8> 4.5	<-23.0> 8.6	53.9%	-2.6	<-24.8> 16.0	-5.3
Royalty	<-16.4> 2.7	<-17.7> 5.7	45.2%	-1.2	<-14.3> 12.5	-2.1
Other subsidiaries	<10.6> 2.2	<13.0> 4.3	50.5%	0.5	<10.7> 8.5	0.8
Pravastatin <antihyperlipidemic>	<-21.5> 11.8	<-20.3> 23.7	53.8%	-6.0	<-20.0> 44.0	-11.0
Mevalotin (JPN)	<-18.9> 10.1	<-18.4> 20.3	54.8%	-4.6	<-19.9> 37.0	-9.2
Other subsidiaries / Export, etc.	<-34.1> 1.7	<-30.2> 3.4	48.7%	-1.5	<-20.6> 7.0	-1.8
Prasugrel (alliance revenue) <antiplatelet>	<-> 1.0	<-> 1.8				
Effient (US)	<-> 0.8	<-> 1.1				
Efient (EU)	<-> 0.2	<-> 0.7				

Forecast of prasugrel is not disclosed.

Total global sales of prasugrel by Eli Lilly and Company for Apr-Sep 2010 is approximately USD 59 mil, of which the U.S. sales is approximately USD 44 mil.

4. Overseas Sales

(Billions of yen)

	FY2010 Results			
	Q2		Q2 YTD	YoY Changes
Overseas sales	<1.6>		<11.2>	
		124.7	258.6	26.1
Overseas sales ratio	51.4%		51.8%	
North America	<8.4>	67.8	145.3	23.9
Europe	<-12.6>	26.0	49.8	-7.1
Other	<1.3>	30.9	63.5	9.3

5. Geographic Segment Information

(Billions of yen)

	FY2010 Results				
	Q2		Q2 YTD	YoY Changes	
Net Sales	<-0.4>		<6.0>		
	100.0	242.5	100.0	498.9	28.3
Japan	<-5.8>	52.6	127.6	52.1	260.1
					-3.8
North America	<15.3>	25.9	62.8	27.1	135.1
					26.4
Europe	<-7.9>	9.3	22.5	8.7	43.2
					-3.8
India	<-2.2>	6.7	16.1	7.1	35.4
					7.4
Other	<6.3>	5.5	13.4	5.0	25.1
					2.1
Operating income	<20.6>		<77.2>		
		29.0		90.1	39.3
Japan		13.9		48.9	
North America		7.3		23.4	
Europe		2.5		4.7	
India		0.5		15.6	
Other		0.9		1.9	

6. Status of Major Companies

* We do not revise forecasts by company and product line.

6-1. Daiichi Sankyo Co., Ltd.

	FY2010 Results				(Billions of yen)
	Q2 YTD	Progress	YoY Changes	FY09 Results ==> FY10 Results	FY2010 Forecast *
					Full Year YoY Changes
Total net sales of ethical pharmaceuticals	<-0.5> 208.3	50.2%	-1.1		<-0.7> 415.0 2.7
Olmetec <antihypertensive>	<7.6> 41.8	48.6%	2.9	Despite competitive market conditions, on the strength of antihypertensive effects and its efficacy for organic protection, sales continued to grow above the market growth rate resulting in a significant sales increase.	<11.4> 86.0 8.8
Rezaltas <antihypertensive>	<-> 1.9	37.7%	1.9	Launched on April 16, 2010.	<-> 5.0 5.0
Calblock <antihypertensive>	<3.5> 7.2	51.4%	0.2	In addition to promotion of long acting antihypertensive effects, prescriptions grew due to its efficacy for renal protection.	<2.3> 14.0 0.3
Artist <antihypertensive>	<0.1> 12.0	53.2%	0.0	Artist prescriptions maintained mainly for cardiac conditions as the only beta-blocker indicated for the treatment of chronic heart failure despite shrinking of the market.	<-3.5> 22.5 -0.8
Mevalotin <antihyperlipidemic agent>	<-18.4> 20.3	54.8%	-4.6	Its clinical efficacy as a standard statin is being promoted but revenues are declining due to increasing prescriptions of generics and competition from strong statins.	<-19.9> 37.0 -9.2
Kremezin <treatment for chronic renal failure>	<2.2> 7.0	54.0%	0.2	Its clear position as oral adsorbent listed in practice guidelines for chronic kidney disease and the clinical efficacy of early administration led to increase in new patients.	<-2.6> 13.0 -0.3
Hanp <treatment for acute cardiac failure>	<-3.9> 4.3	50.7%	-0.2	Although Hanp maintained its strong market position as first choice for treatment of acute heart failure, the market diminished with the expansion in Diagnosis Procedure Combination (DPC) causing sales to slightly decrease.	<-10.0> 8.5 -0.9
Livalo <antihyperlipidemic agent>	<8.9> 4.0	49.8%	0.3	Sales increased leveraging the announcement of evidence of studies on Japanese and the growth of the strong statin market.	<9.7> 8.0 0.7
Sunrythm <antiarrhythmic agent>	<-7.2> 5.6	53.0%	-0.4	Although Sunrythm ensured its market position due to its competitive edge as the first choice prescription for patients with atrial fibrillation, its sales decreased slightly with the increase of generic prescriptions and due to the diminishing antiarrhythmic agent market.	<-8.6> 10.5 -1.0
Fastic <antidiabetic agent>	<-6.6> 2.6	51.0%	-0.2	Sales slightly decreased due to the expansion of competitive glinide agents and entry of DPP-4 inhibitor into the market.	<-3.2> 5.0 -0.2
Cravit <synthetic antibacterial agent>	<-28.5> 15.3	46.4%	-6.1	Sales decreased due to continuing slowdown in antibiotic market despite its strong appeal as effective control against drug-resistant bacteria based on PK/PD theory.	<-24.4> 33.0 -10.6
Loxonin <anti-inflammatory analgesic>	<13.3> 26.9	52.7%	3.2	While the market for Loxonin in oral and pap form remains sluggish, sales increased due to growth in the tape market and its superior qualities and strong brand name.	<8.6> 51.0 4.0
Urief <treatment for dysuria>	<10.2> 4.9	42.8%	0.5	Despite difficult market environment, the number of prescriptions increased and sales grew due to its high efficacy.	<27.3> 11.5 2.5
Zyrtec <antiallergic agent>	<-8.6> 3.8	47.6%	-0.4	As the market was sluggish due to small amount of pollen dispersion, sales slightly decreased.	<-16.3> 8.0 -1.6
Omnipaque <contrast agent>	<-11.3> 13.0	56.6%	-1.7	While Omnipaque secured top share by such as expanding its lineups to match treatment needs, sales declined due to increased prescriptions of generic drugs following the expansion of DPC.	<-15.6> 23.0 -4.3

6-2. Daiichi Sankyo Healthcare Co., Ltd

	FY2010 Results				(Billions of yen)
	Q2 YTD	Progress	YoY Changes	FY09 Results ==> FY10 Results	FY2010 Forecast *
					Full Year YoY Changes
Daiichi Sankyo Healthcare Co., Ltd	<-8.6> 21.0	43.3%	-2.0		<10.9> 48.5 4.8
LuLu Series	<-6.6> 5.2	44.5%	-0.4	Sales decreased due to difficult market environment.	<16.8> 11.6 1.7
Gaster 10	<-3.1> 1.0	36.9%	0.0	Sales slightly fell due to the continuing impact of the revised Pharmaceutical Affairs Act.	<27.0> 2.6 0.6
Daiichi Sankyo Ichoyaku series	<-10.2> 1.6	42.8%	-0.2	Sales decreased due to difficult market and competitive environments.	<4.6> 3.7 0.2
Patecs series	<-22.1> 1.2	47.4%	-0.3	Sales decreased due to difficult market and competitive environments.	<4.4> 2.6 0.1
Transino	<-9.1> 0.4	25.8%	0.0	Sales fell due to the continuing impact of the revised Pharmaceutical Affairs Act.	<56.0> 1.4 0.5

6-3. Daiichi Sankyo, Inc. (US)

	FY2010 Results				(Billions of yen)
	Q2 YTD	Progress	YoY Changes	FY09 Results ==> FY10 Results	FY2010 Forecast *
					Full Year YoY Changes
Daiichi Sankyo, Inc. (DSI)	<1.5> 67.5	46.5%	1.0		<9.0> 145.0 12.0
mil USD	<8.9> 759	47.1%	62		<12.5> 1,611 178
Benicar / Benicar HCT <antihypertensive>	<-4.9> 42.1	47.1%	-2.2	With the impact of competitor product generics beginning to be observed amid the slowing down of the ARB market growth rate on a prescription basis, DSI will continue to actively promote Benicar / Benicar HCT, leveraging the superior antihypertensive effect data obtained from direct comparative clinical trials.	<0.6> 89.5 0.6
mil USD	<2.1> 474	47.6%	10		<3.8> 994 37
Azor <antihypertensive>	<16.1> 7.2	55.3%	1.0	Achieved higher growth rate than competitive products on a prescription basis, through promotional activities ensuring Azor's position as a unique product.	<1.7> 13.0 0.2
mil USD	<24.7> 81	56.0%	16		<5.0> 144 7
Tribenzor <antihypertensive>	<-> 0.7	-	0.7	Since its launch in August, growth has been satisfactory. DSI will implement active promotional activities to ensure market penetration.	<-> - -
mil USD	<-> 7	-	7		<-> - -
Welchol <antihyperlipidemic / type 2 diabetes>	<7.4> 14.4	50.4%	1.0	Enhanced promotional activities leveraging its attribute as the only therapy approved to treat patients with type 2 diabetes and primary hyperlipidemia. The newly introduced drinkable oral suspension was vital element behind the expansion of prescriptions and efforts are focused on further input.	<3.5> 28.5 1.0
mil USD	<15.3> 162	51.0%	21		<6.8> 317 20
Effient (alliance revenue) <antiplatelet>	<-> 1.1	-	-	Formulary acceptance and hospital adoption steadily increased. While aggressively approaching KOL for better understandings, active promotional activities are aimed at better suiting market needs such as sales force shift, and further strengthening efforts to gain new prescriptions.	
mil USD	<-> 13	-	-		

Forecast of Effient is not disclosed.

* We do not revise forecasts by company and product line.

6-4. Luitpold Pharmaceuticals, Inc. (US)

	FY2010 Results				(Billions of yen)
	Q2 YTD	Progress	YoY Changes	FY09 Results ==> FY10 Results	FY2010 Forecast *
Luitpold Pharmaceuticals, Inc. (LPI)	<5.8>				<-9.8>
	28.4	60.5%	1.6		47.0
mil USD	<13.6>				<-6.9>
	319	61.2%	38		522
Venofer	<0.1>				<-16.0>
<treatment for iron deficiency anemia>	16.1	59.8%	0.0	Through an exclusive sublicensing agreement for the US dialysis market with Fresenius Medical Care, the largest dialysis chain company in the world, the share of Venofer in this company continued to increase. Sales increased steadily in the non-dialysis markets, where LPI concentrates its activities, through approaches to hematology specialists and hospitals and by the delay in launch of generic drugs.	27.0
mil USD	<7.4>				<-13.4>
	181	60.5%	13		300
					-46

6-5. Daiichi Sankyo Europe GmbH

	FY2010 Results				(Billions of yen)
	Q2 YTD	Progress	YoY Changes	FY09 Results ==> FY10 Results	FY2010 Forecast *
Daiichi Sankyo Europe GmbH (DSE)	<-12.2>				<0.4>
	31.4	41.6%	-4.4		75.5
mil €	<2.7>				<9.7>
	276	43.8%	7		629
Olmetec / Olmetec Plus	<-5.6>				<2.7>
<antihypertensive>	17.2	42.0%	-1.0	DSE strengthened promotional activities in major countries and sales of both Olmetec and Olmetec Plus steadily grew. Sales of co-marketing partners also remained firm. While it is important to watch the trend and impact of price cut measures by European governments, DSE will further strengthen its activities including the use of evidence of large-scale clinical trials.	41.0
mil €	<10.4>				<12.3>
	151	44.3%	14		342
Sevikar	<92.0>				<50.0>
<antihypertensive>	4.0	42.6%	1.9	First launched in Germany in January 2009, the number of European countries where Sevikar is available continued to increase. Sales have firmly expanded on the back of promotional activities emphasizing Sevikar's safety as well as efficacy.	9.5
mil €	<124.6>				<64.0>
	36	44.9%	20		79
Evista	<-33.3>				<-12.7>
<treatment for osteoporosis>	3.3	41.6%	-1.7	Although DSE has gradually shifted to own company promotion in each country and taken steps to maintain the sales level, sales are trending downwards.	8.0
mil €	<-22.0>				<-4.6>
	29	43.9%	-8		67
					-3

Alliance Revenue of Efient (Europe)

Efient	<->			
<antiplatelet>	0.7	-	-	Launched promotional activities in UK and Germany in March 2009. Efient is now available in ten European countries and DSE is strengthening activities to gain new prescriptions and gearing towards continuous expansion of prescriptions.
mil USD	<->			
	8	-	-	

Alliance revenue of Efient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include such revenue.

Forecast of Efient is not disclosed.

* We do not revise forecasts by company and product line.

6-6. Asia, South and Central America (ASCA)

	FY2010 Results				(Billions of yen)
	Q2 YTD	Progress	YoY Changes	FY09 Results ==> FY10 Results	FY2010 Forecast *
					Full Year YoY Changes
ASCA Total	<12.7> 13.0	46.4%	1.5	Increase by 23.1% excluding the forex impact.	<8.6> 28.0 2.2
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<10.3> 2.2	57.5%	0.2	Increase by 15.1% on a local currency basis. In addition to the sales increase of Cravit, DSBJ also contributed to the sales increase of DSSH products (Carbenin).	<-4.9> 3.9 -0.2
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	<33.9> 3.2	46.8%	0.8	Increase by 39.7% on a local currency basis. In addition to the expansion of Olmesartan, Loxonin and Asmeton, increased sales of Carbenin promoted by DSBJ, made a contribution.	<26.7> 6.7 1.4
Daiichi Sankyo Taiwan Ltd. (DSTW)	<-3.9> 1.6	51.9%	-0.1	Decrease by 0.2% on a local currency basis. Sales of intravenous formulation of Cravit and Olmesartan franchise increased.	<-0.5> 3.1 0.0
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<16.1> 1.9	39.9%	0.3	Increase by 15.9% on a local currency basis. Sales growth of Sevikar made a contribution.	<39.4> 4.7 1.3
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<28.2> 0.5	38.2%	0.1	Increase by 28.2% on a local currency basis. In addition to the increased sales of Cravit following the launch of Cravit i.v. 750mg, sales of Mevalotin contributed to the growth.	<55.1> 1.4 0.5
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	<38.3> 2.5	44.0%	0.7	Increase by 20.9% on a local currency basis. Sales growth of Benicar franchise including the combination drug (Olmesartan and Amlodipine) contributed to the increase.	<19.0> 5.6 0.9
Daiichi Sankyo Venezuela, S.A. (DSVE)	<-31.0> 1.1	38.1%	-0.5	Increase by 45.5% on a local currency basis. The launch of combination drug (Olmesartan and Amlodipine) contributed to the growth of Benicar franchise.	<-30.6> 2.9 -1.3

6-7. Ranbaxy Laboratories Limited

	FY2010 Results				(Billions of yen)
	Q2 YTD	Progress	YoY Changes	FY09 Results ==> FY10 Results	FY2010 Forecast *
					Full Year YoY Changes
Ranbaxy Laboratories Limited	<49.0> 98.5	59.7%	32.4		<12.6> 165.0 18.4

7. Number of Employees

	FY2009	FY2010	
	Mar-10	Jun-10	Sep-10*
Total Number of Employees	29,825	30,194	30,424
Japan	8,892	9,061	9,048
Overseas	20,933	21,133	21,376

		FY2009		FY2010			
		Mar-10	MRs	Jun-10	MRs	Sep-10*	MRs
Total Number of Employees		29,825		30,194		30,424	
<Japan>							
Daiichi Sankyo Co., Ltd.	(DS)	6,028	2,400	6,210	2,400	6,182	2,400
Daiichi Sankyo Healthcare Co., Ltd	(DSHC)	391	150	394	150	392	150
<US>							
Daiichi Sankyo, Inc.	(DSI)	2,940	1,800	2,911	1,800	2,897	1,800
Luitpold Pharmaceuticals, Inc.	(LPI)	611	80	636	80	633	80
<Europe>							
Daiichi Sankyo Europe GmbH	(DSE)	2,432	1,340	2,460	1,370	2,470	1,370
<Asia / Latin America>							
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd.	(DSBJ)	490	178	493	182	495	183
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.	(DSSH)	565	247	570	263	584	267
Daiichi Sankyo Taiwan Ltd.	(DSTW)	163	70	162	68	164	67
Daiichi Sankyo Korea Co., Ltd.	(DSKR)	98	50	101	51	101	51
Daiichi Sankyo (Thailand) Ltd.	(DSTH)	54	30	51	24	53	25
Daiichi Sankyo Hong Kong Ltd.	(DSHK)	7	-	7	-	7	-
Daiichi Sankyo Brasil Farmacêutica Ltda.	(DSBR)	307	119	313	118	308	117
Daiichi Sankyo Venezuela, S.A.	(DSVE)	141	84	140	76	161	86

	FY2009	FY2010	
	Mar-10	Jun-10	Sep-10*
Ranbaxy Group	12,995	13,157	13,405

* For overseas subsidiaries with different fiscal year-ends, figures as of Jun-10 are shown

8. Major Management / Financial Indicators

	FY2009 Results		FY2010 Results	(Billions of yen) FY2010 Forecast
	Q2 YTD	Full Year	Q2 YTD	Full Year
Management Indicators				
Dividend payout ratio (Consolidated)	113.0%	100.9%	40.5%	76.8%
Dividend on equity (DOE)	-	4.9%	-	-
Earnings per share (EPS)	26.6yen	59.4yen	74.1yen	78.1 yen
Dividend per share	30.0 yen	60.0 yen	30.0yen	60.0 yen
Dividend payment (billions of yen)	21.1	42.2	211.0	-
Return on equity (ROE)	-	4.9%	6.1%	-
Book value per share (BPS)	1,213.8 yen	1,215.6 yen	1,212.7yen	-
Equity ratio	58.5%	57.4%	58.3%	-
Number of treasury stock purchased	-	-	-	-
Treasury stock purchase (billions of yen)	-	-	-	-
Total number of common shares*	704 million	704 million	704million	-
Share price at end of period	1,853 yen	1,751 yen	1,698yen	-
Market value (billions of yen)	1,304.4	1,232.6	1,195.3	-
Financial Indicators (billions of yen)				
Total assets	1,460.3	1,489.5	1,465.0	
Current assets	771.5	819.8	843.6	
Debt with interest	318.5	290.9	299.4	
Shareholder's equity	854.4	855.7	853.6	
CF from operating activities	39.6	130.2	77.3	
CF from investing activities	54.9	42.6	-25.2	
CF from financial activities	-42.0	-89.1	-10.8	
Free cash flow**	94.5	172.9	52.1	
Cash and cash equivalents, end of year	227.6	259.2	291.0	
Liquidity on hand***	341.2	358.3	401.0	
Number of consolidated subsidiaries	96	99	98	

* excluding treasury stock

** CF from operating activities + CF from investing activities

*** Current deposits + marketable securities + investment securities, etc

9. Capital Expenditure and Depreciation and Amortization Expense

	FY2009 Results		FY2010 Results	(Billions of yen) FY2010 Forecast
	Q2 YTD	Full Year	Q2 YTD	Full Year
Capital expenditure	12.7	29.7	15.3	45.0
Depreciation and amortization expense	22.0	45.9	21.3	48.5
Tangible assets	13.9	28.8	12.9	
Intangible assets	8.2	17.1	8.4	

10. Number of Shares Held and Shareholders by Category

	As of September 30, 2009			As of March 31, 2010			As of September 30, 2010		
	Number of shareholders	Number of shares (million)	%	Number of shareholders	Number of shares (million)	%	Number of shareholders	Number of shares (million)	%
Government and public	2	0	0.0%	2	0	0.0%	2	0	0.0%
Financial institutions	188	326	46.1%	172	310	43.8%	172	318	44.9%
Financial instruments firms	86	19	2.7%	84	19	2.6%	78	21	3.0%
Corporate investors	800	46	6.5%	793	46	6.5%	802	46	6.5%
Foreign investors	672	199	28.3%	619	212	29.9%	609	193	27.3%
individuals	94,070	111	15.7%	98,454	116	16.4%	105,333	124	17.6%
Treasury stock	1	5	0.7%	1	5	0.7%	1	5	0.7%
Total	95,819	708	100.0%	100,125	708	100.0%	106,997	708	100.0%

11. Consolidated Balance Sheets

<Assets>

(Billions of yen)

	2010.3.31		2010.9.30		Change	Details
		%		%		
Current assets	819.8	55.0	843.6	57.6	23.9	
Cash and time deposits	101.0		135.5		34.5	Liquidity on hand (cash and time deposits + marketable securities + investment securities, etc.) <u>Total ¥ 401.0 billion (¥ +42.7 billion from the end of fiscal 2009)</u>
Trade notes and accounts receivable	211.9		207.7		-4.2	
Marketable securities	236.5		255.0		18.4	
Inventories	143.2		141.0		-2.2	Breakdown of inventories as of September 30, 2010 Merchandise and finished goods: ¥ 88.4 billion Work in process: ¥ 17.2 billion Raw materials and supplies: ¥ 35.5 billion
Deferred tax assets	87.0		70.6		-16.4	
Other current assets	41.8		35.5		-6.3	
Allowance for doubtful accounts	-1.7		-1.6		0.0	
Non-current assets	669.8	45.0	621.4	42.4	-48.4	
Property, plant and equipment	249.5	16.8	236.6	16.1	-13.0	
Buildings and structures, net	126.6		120.1		-6.5	Transfer of Shizuoka Factory etc.
Machinery, equipment and vehicles, net	44.5		43.0		-1.5	
Land	42.6		39.3		-3.3	
Construction in progress	22.3		20.9		-1.4	
Other, net	13.5		13.2		-0.3	
Intangible assets	180.9	12.1	164.6	11.2	-16.3	
Goodwill, net	73.8		68.6		-5.2	Amortization: U3 Pharma: ¥ -2.5 bil, Ranbaxy: ¥ -1.2 bil
Other intangible assets, net	107.1		96.0		-11.1	Forex, Amortization of Ranbaxy and sales rights of Evista in Europe, etc.
Investments and other assets	239.3	16.1	220.2	15.0	-19.1	
Investment securities	137.0		111.6		-25.4	Decrease in net unrealized gain on investment securities
Prepaid pension costs	3.9		2.1		-1.8	
Deferred tax assets	81.8		90.3		8.5	
Other	16.9		16.5		-0.4	
Allowance for doubtful accounts	-0.3		-0.3		0.0	
Total assets	1,489.5	100.0	1,465.0	100.0	-24.5	

<Liabilities and Net Assets>

(Billions of yen)

	2010.3.31		2010.9.30		Change	Details
		%		%		
Liabilities	600.0	40.3	572.9	39.1	-27.1	
Current liabilities	268.8	18.0	298.0	20.3	29.1	
Trade notes and accounts payable	66.5		67.4		0.8	
Short-term bank loans	20.0		32.7		12.7	
Convertible bond-type bonds with subscription rights to shares to be redeemed within one year	-		49.0		49.0	---- Change from long-term financing
Income taxes payable	10.6		9.7		-1.0	
Allowance for sales returns	0.6		0.8		0.2	
Allowance for sales rebates	1.4		1.3		-0.1	
Allowance for contingent losses	1.6		1.8		0.2	
Other current liabilities	168.1		135.3		-32.7	
Long-term liabilities	331.2	22.2	274.9	18.8	-56.3	
Bonds payable	100.0		100.0		0.0	
Convertible bond-type bonds with subscription rights to shares	49.5		-		-49.5	---- Change to short-term financing
Long-term debt	121.4		117.7		-3.7	
Deferred tax liabilities	29.2		25.9		-3.3	
Accrued employees' severance and retirement benefits	12.3		11.7		-0.6	
Accrued directors' severance and retirement benefits	0.1		0.1		0.0	
Other long-term liabilities	18.6		19.4		0.9	
Net assets	889.5	59.7	892.1	60.9	2.6	
Shareholders' equity	887.0	59.6	918.1	62.7	31.0	
Common stock	50.0		50.0		0.0	
Capital surplus	105.2		105.2		0.0	
Retained earnings	746.4		777.4		31.0	Dividends paid: <u>¥ -21.1 bil</u> Net income: <u>¥ +52.2 bil</u>
Treasury stock, at cost	-14.6		-14.6		0.0	
Valuation and translation adjustments	-31.3	-2.1	-64.4	-4.4	-33.1	
Net unrealized gain on investment securities	27.5		17.4		-10.1	
Deferred gains or losses on hedges	1.0		0.9		-0.1	
Foreign currency translation adjustments	-59.8		-82.7		-23.0	
Subscription rights to shares	3.3	0.2	3.6	0.2	0.3	
Minority interests	30.5	2.0	34.9	2.4	4.4	
Total liabilities and net assets	1,489.5	100.0	1,465.0	100.0	-24.5	

12. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2009 Q2 YTD	FY2010 Q2 YTD	Change	
Income before income taxes and minority interests	53.7	94.1	40.5	
Depreciation	22.0	21.3	-0.7	
Amortization of goodwill	4.4	4.5	0.1	
(Gain) loss on valuation of derivatives	-8.7	-4.7	4.0	
(Gain) loss on valuation of investments securities	0.1	3.2	3.1	
(Gain) loss on sales of investment securities	-1.8	-2.9	-1.0	
(Gain) loss on sales and disposal of property, plant and equipment	0	-3.8	-3.8	
(Increase) decrease in trade notes and accounts receivable	-20.7	-3.0	17.6	
(Increase) decrease in inventories	-3.5	-3.8	-0.3	
Increase (decrease) in trade notes and accounts payable	-2.1	3.3	5.4	
Increase (decrease) in accounts payable and accrued expenses	-7.4	-6.5	0.9	
Other, net	17.6	-3.7	-21.3	--- FY2009: Refund of income taxes paid in FY2008
Income taxes paid	-14.0	-20.8	-6.8	
Cash flows from operating activities	39.6	77.3	37.8	
Net (increase) decrease in short-term operating assets	68.4	-20.8	-89.1	
(Acquisitions) / proceeds from sales of property, plant and equipment	-13.0	-10.6	2.4	
(Acquisitions) / proceeds from sales of investment securities	0.2	4.0	3.8	
Proceeds from sales of investments in consolidated subsidiaries	0.0	5.6	5.6	--- Transfer of Shizuoka Factory
Other, net	-0.7	-3.5	-2.8	
Cash flows from investing activities	54.9	-25.2	-80.1	
Net increase (decrease) in short-term bank loans and long-term debt	-113.4	10.3	123.7	
Proceeds from issuance of bonds	99.7	0.0	-99.7	
Dividends paid	-28.1	-21.1	7.0	
Other, net	-0.1	0.0	0.2	
Cash flows from financing activities	-42.0	-10.8	31.2	
Effect of exchange rate changes on cash and cash equivalents	-2.6	-9.5	-6.9	
Net increase (decrease) in cash and cash equivalents	49.8	31.8	-18.1	
Cash and cash equivalents, beginning of period	177.8	259.2	81.4	
Cash and cash equivalents, end of period	227.6	291.0	63.4	

(This page is intentionally left blank)

13. Major R&D Pipeline

Daiichi Sankyo Group Major Research & Development Pipeline (Development Stage)

Therapeutic Area	Main Existing Product	Phase1	Phase2
Cardiovascular diseases	Mevalotin Benicar/Olmetec Azor/Sevikar Tribenzor Welchol Effient/Efient Olmetec Rezaltas Calblock Artist Mevalotin Kremezin Hanp Livalo Sunrythm Bepricor	DB-772d (oral factor Xa inhibitor)	DU-176b(US/EU) (Edoxaban / post surgical VTE / oral factor Xa inhibitor) CS-747(JP) (Prasugrel / anti-platelet agent)
Diabetes mellitus	Welchol Fastic		CS-1036(JP/Asia) (glucose absorption inhibitor)
Cancer	Topotecin Krestin	 CS-7017(JP/Asia) (PPARγ activator)	U3-1287(US/EU) (anti-HER3 antibody) CS-1008(US/EU/JP/Asia) (Tigatuzumab / anti-DR5 antibody) CS-7017(US/EU) (PPARγ activator) DE-766(JP) (Nimotuzumab / anti-EGFR antibody) ARQ 197(US/EU) (c-Met inhibitor)
Infectious diseases	Levaquin / Tavanic Banan Cravit	CS-8958(US/EU) (Laninamivir / anti-influenza / co-development with Biota) CS-4771 (Sepsis) DS-8587 (Broad spectrum antibacterial agents)	
Bone/Joint diseases	Loxonin Mobic		
Immunological allergic diseases	Zyrtec	CS-0777 (immunomodulator)	SUN13834(US) (chymase inhibitor)
Others	Venofor Evoxac Omnipaque Omniscan Visipaque Sonazoid Feron Urief	DS-5565 (Chronic pain)	SUN11031(US/EU) (Human ghrelin / cachexia) 

★Additional indications, new formulations etc.

Change from the announcement in July 2010

New(underline)

Change of Stage etc.

AMG 162(Breast cancer adjuvant / JP / P3), DS-5565(Chronic Pain/ P1)

CS-8958(anti-influenza/ treatment/ JP/ Approved & Launched), Levofloxacin inj (new quinolone / JP/ Approved),

U3-1287(Anti-Her3 Antibody/ US/ EU/ P2), CS-1008(Anti- DR5 Antibody/ JP/ P2)

Phase3	Application
☆CS-747(US/EU/Asia) (Prasugrel / ACS-MM / anti-platelet agent) DU-176b(US/EU/JP/Asia) (Edoxaban / AF / oral factor Xa inhibitor) DU-176b(US/EU/JP/Asia) (Edoxaban / VTE / oral factor Xa inhibitor)	☆CS-8635(EU) (Olmesartan, Amlodipine, Hydrochlorothiazide combination) DU-176b(JP) (Edoxaban / post surgical VTE / oral factor Xa inhibitor)
☆CS-8958(JP) (Laninamivir / prophylactic / anti-influenza)	☆Levofloxacin inj(JP) (new quinolone) CS-8958(JP) (Laninamivir / treatment / anti-influenza)
AMG 162(JP) (Denosumab / osteoporosis, <u>breast cancer adjuvant</u> / anti-RANKL antibody)	AMG 162(JP) (Denosumab / bone metastases of cancer/ anti-RANKL antibody)
SUN11031(JP) (Human ghrelin / anorexia nervosa) ☆DD-723-B(JP) (Perflubutane / ultrasound contrast agent)	KMD-3213(China) (Silodosin / treatment of dysuria associated with benign prostatic hyperplasia) SUN Y7017(JP) (Memantine / Alzheimer's type Dementia)

AMG 162 (Bone metastases of cancer/ JP/ Application), ☆DD-723-B(Ultrasound contrast agent/ JP/ P3),

Cardiovascular diseases

【project after Phase II】

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-747	prasugrel	Oral	Anti-platelet agent	1) Acute coronary syndrome 2) Ischemic stroke	DAIICHI SANKYO, Ube Industries	US/EU/Asia JP	1) P3, 2) - 1) P2, 2) P2
- Inhibition platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate(ADP) receptor on the platelet surface. - Co-development with Eli Lilly in the US and EU, development by DAIICHI SANKYO in Japan - In June, 2008, a new Phase3 trial started in US and EU for patients with acute coronary syndrome, not being managed with percutaneous coronary intervention (ACS-MM). [EU] Approved in Feb-2009 for ACS-PCI [US] Approved in Jul-2009 for ACS-PCI [JP] P2 studies for elective PCI and ischemic stroke are on-going.							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DU-176b	edoxaban	Oral	Factor Xa inhibitor	1) Atrial fibrillation (AF) 2) Venous thromboembolism (VTE) 3) Post surgical VTE	DAIICHI SANKYO	US/EU JP Asia	1)P3, 2)P3, 3) P2 1)P3, 2)P3, 3) Appl. 1)P3, 2)P3, 3) -
- An oral anticoagulant that directly inhibits Xa factor playing an important role in the process when blood coagulates. - An oral factor Xa inhibitor, possible once daily regimen with high oral absorption, confirmed by clinical trials. - No severe hepatotoxicity signals in pre-clinical and clinical trials - Development by DAIICHI SANKYO globally - A P3 multi-national trial in AF started in Nov-2008. (ENGAGE AF-TIMI48) - A P3 multi-national trial for prevention of recurrent VTE in patients with deep-vein thrombosis and/or pulmonary embolism started in Jan-2010.(HOKUSAI VTE) - Top line results for a Japanese P3 trial in VTE after surgery were announced in Dec-2009. [JP] Application for the prevention of VTE after major orthopedic surgery: Mar-2010.							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-8635	olmesartan medoxomil amlodipine hydrochlorothiazide	Oral	Angiotensin II receptor antagonist Calcium channel blocker Diuretic	Hypertension	DAIICHI SANKYO	EU	Application
- Combination drug of Olmesartan (angiotensin II receptor antagonist), Amlodipine(calcium channel blocker) and Hydrochlorothiazide(diuretic) - LCM of Olmesartan [EU] Application:Dec-2009 [US] Approved:Jul.-2010							

Diabetes mellitus

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-1036	-	Oral	Glucose absorption inhibitor	Diabetes mellitus	DAIICHI SANKYO	JP/Asia	P2
- Inhibition of degrading starch and glucose absorption - A P2 trial for Type 2 DM patients is ongoing							

Cancer

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
ARQ 197	-	Oral	c-Met inhibitor	-	ArQule	US/EU	P2
- c-Met has multiple roles in intracellular signal transductions such as cancer cell motility, proliferation, angiogenesis, invasion, and apoptosis induction. - Variations of c-Met are shown in gastric, HCC, head and neck cancer, and high expression of c-met are shown in colon, HCC, pancreatic, prostate, breast cancer, etc. - Clinical studies are on-going for several types of cancer. - A P3 clinical trial for NSCLC is in preparation.							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-1008	tigatuzumab	Injection	Anti-DR5 antibody	-	DAIICHI SANKYO	US/EU JP/Asia	P2
- A humanized version TRA-8, a murine agonistic Mab raised against human death receptor 5(DR5). - DR5 is rarely expressed in normal tissues, expected to show selective activity against tumor cells. - Induces apoptosis of tumor cells expressing DR5 on the cell surface. - Clinical studies are on-going for several types of cancer.							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DE-766	nimotuzumab	Injection	Anti-EGFR antibody	-	CIMYM Biosciences	JP	P2
- A humanized monoclonal antibody against Epidermal Growth Factor Receptor(EGFR). - Expected to be a best in class EGFR antibody, safety against the skin toxicity and the efficacy comparable to the other EGFR antibodies. - Clinical studies are on-going for several types of cancer.							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-7017	-	Oral	PPAR-gamma activator	-	DAIICHI SANKYO	US/EU JP/Asia	P2 P1
- Inhibits growth of tumor cells in vitro without killing those cells. - Expected to be less toxic compared to standard chemotherapeutics. - Clinical studies are on-going for several types of cancer.							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
U3-1287	-	Injection	Anti-HER3 antibody	-	DAIICHI SANKYO (U3 Pharma)	US/EU	P2
- HER 3 is one of the member of the Epidermal Growth Factor Receptor(EGFR) family of proteins. - HER3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce cell proliferation than homodimers of HER2 or EGFR - Clinical studies are on-going for several types of cancer.							

Infectious diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-8958	Ianinamivir	Inhalant	Neuraminidase inhibitor	Influenza, 1) Treatment, 2) Prophylactic	DAIICHI SANKYO	US/EU JP	P1 1) Approved, 2) P3
- CS-8958 is a long-acting neuraminidase inhibitor that is expected to be used as single administration for treatment and once a week for prophylaxis. - Licensing activity with Biota in the US and EU, development by DAIICHI SANKYO in Japan - CS-8958 is under development as an inhalant that will act directly on the pulmonary and tracheal sites of infection. [JP] Approved for the flu treatment: Sep-2010							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
levofloxacin inj	levofloxacin	Injection	New quinolone	Bacterial infections	DAIICHI SANKYO	JP	Approved
- The drug inhibits bacterial DNA composition by inhibiting a DNA gyrase activity and a topoisomerase IV activity. - New formulation(injection of levofloxacin) - Approved: Oct-2010							

Immunological allergic diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN 13834	-	Oral	Chymase inhibitor	Atopic Dermatitis	DAIICHI SANKYO (Asubio Pharma)	US	P2
- Inhibiting chymase, one of endogenous proteases, which is released from mast cells and involves allergic reaction. - Expected to be an oral anti-atopic dermatitis drug with a novel mechanism of action.							

Bone/Joint diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
AMG 162	denosumab	Injection	Anti-RANKL antibody	1) Bone metastases of cancer 2) Osteoporosis 3) Breast cancer adjuvant	Amgen	JP	1) Application 2,3) P3
- Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the resorptive phase of bone remodeling. - July, 2007 In-licensed from Amgen - P3 : Osteoporosis, Breast cancer adjuvant - Application: Bone metastases of cancer in Aug-2010							

Others

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN Y7017	memantine	Oral	NMDA receptor antagonist	Dementia of Alzheimer type	Merz	JP	Application
- Memantine, categorized as an antagonist of the NMDA receptor which is one of the Glutamate receptor subtypes in the central nervous system in mammals, possesses therapeutic action for dementia of Alzheimer type. The drug is expected to demonstrate effectivity in slowing down the progression of the disease by its neuroprotective action, which is distinct from cholinesterase inhibitors. - Application: Feb-2010							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
KMD-3213	silodosin	Oral	Selective alpha 1A blocker	Treatment of dysuria associated with benign prostatic hyperplasia	Kissei	China	Application
- An alpha1A blocker which effectively reduces urinary tract resistance and improves dysuria associated with benign prostatic hyperplasia. - Reduces cardiovascular side effects due to its alpha1A selectivity. - Silodosin is marketed in Japan as brand name of UR1EF by DAIICHI SANKYO and Kissei. - Development by DAIICHI SANKYO in China - Application: Dec-2008							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN 11031	human ghrelin	Injection	Appetite stimulation/ Increase gastric motility	Cachexia Anorexia Nervosa	DAIICHI SANKYO (Asubio Pharma)	US/EU JP	P2 P3
- Ghrelin is an endogenous peptide known as one-and-only peripheral appetite stimulator among all hormones discovered the relationship with feeding behavior up to now. In addition to it, ghrelin is a potent stimulator of growth hormone release. - P2 study for cachexia in US/EU, and P3 study for anorexia nervosa are on-going.							
Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DD-723-B	perflubutane	Injection	Ultrasound contrast agent	Contrast for prostatic tumor Contrast for mammary tumor	GEHC	JP	P2 P3
DD-723-B is marketed in Japan as a brand name of SONAZOID® for injection.							

1. Summary of Income Statement

(Billions of yen)

	FY2009									
	Q1		Q2		Q3		Q4		Full Year	
Net sales	<11.5> 100.0	227.1	<20.2> 100.0	243.4	<15.3> 100.0	255.1	<5.6> 100.0	226.4	<13.1> 100.0	952.1
Cost of Sales	27.5	62.5	30.7	74.7	29.6	75.4	28.9	65.4	29.2	278.0
Selling, general and administrative expenses	60.7	137.8	59.4	144.6	55.1	140.5	68.7	155.6	60.8	578.6
Research and development expenses	19.9	45.1	20.1	49.0	18.7	47.6	24.3	55.1	20.7	196.8
Other expenses	40.8	92.7	39.3	95.6	36.4	92.9	44.4	100.5	40.1	381.8
Operating income	<-33.1> 11.8	26.8	<11.5> 9.9	24.1	<7.6> 15.4	39.2	<-> 2.4	5.4	<7.5> 10.0	95.5
Non-operating income		3.9		10.9		4.3		9.1		28.2
Non-operating expenses		23.5		-10.1		5.1		2.1		20.6
Ordinary income	<-82.5> 3.2	7.2	<140.0> 18.5	45.1	<14.4> 15.0	38.4	<-> 5.5	12.5	<86.9> 10.8	103.1
Extraordinary gains		2.1		0.2		1.5		2.1		5.9
Extraordinary losses		0.7		0.3		2.5		8.1		11.6
Income before income taxes and minority interests	3.8	8.6	18.5	45.0	14.6	37.3	2.8	6.4	10.2	97.4
Income taxes		24.0		12.8		16.0		-2.7		50.0
Minority interests		-8.9		7.1		0.7		6.5		5.5
Net income	<-> -	-6.4	<182.7> 10.3	25.1	<-> 8.1	20.6	<-96.8> 1.2	2.6	<-> 4.4	41.9

	FY2010					
	Q1		Q2		Q2 YTD	
Net sales	<12.9>		<-0.4>		<6.0>	
	100.0	256.4	100.0	242.5	100.0	498.9
Cost of Sales	25.0	64.1	30.7	74.4	27.8	138.5
Selling, general and administrative expenses	51.2	131.3	57.3	139.0	54.2	270.3
Research and development expenses	17.0	43.6	18.9	45.7	17.9	89.3
Other expenses	34.2	87.7	38.5	93.3	36.3	181.0
Operating income	<128.1>		<20.6>		<77.2>	
	23.8	61.1	12.0	29.0	18.1	90.1
Non-operating income		11.8		-1.7		10.1
Non-operating expenses		2.8		4.8		7.6
Ordinary income	<-877.7>		<-50.0>		<77.3>	
	27.3	70.1	9.3	22.6	18.6	92.6
Extraordinary gains		0.8		6.8		7.6
Extraordinary losses		4.8		1.3		6.1
Income before income taxes and minority interests	25.8	66.1	11.6	28.0	18.9	94.1
Income taxes		26.6		8.2		34.7
Minority interests		6.5		0.8		7.3
Net income	<->		<-24.1>		<179.0>	
	12.9	33.1	7.9	19.1	10.5	52.2

<Daiichi Sankyo Group>

(Billions of yen)

		FY2009									
		Q1		Q2		Q3		Q4		Full Year	
Net sales		<-3.1>		<2.2>		<-1.0>		<3.4>		<0.2>	
		100.0	197.4	100.0	207.0	100.0	219.1	100.0	181.9	100.0	805.5
Cost of Sales		23.0	45.4	26.2	54.3	25.4	55.6	26.0	47.3	25.2	202.6
Selling, general and administrative expenses		61.8	122.0	61.1	126.5	56.8	124.3	74.1	134.8	63.0	507.6
Research and development expenses		21.8	43.0	22.6	46.7	20.6	45.2	28.4	51.6	23.2	186.5
Other expenses		40.0	79.0	38.5	79.8	36.1	79.1	45.7	83.2	39.9	321.1
Operating income		<-24.9>		<21.3>		<-6.7>		<->		<-11.5>	
		15.2	30.0	12.7	26.2	17.9	39.1	-0.1	-0.2	11.8	95.2
Non-operating income			2.9		2.0		1.8		0.4		7.1
Non-operating expenses			0.8		1.8		2.2		1.4		6.1
Ordinary income		<-21.3>		<40.5>		<-0.8>		<->		<-2.3>	
		16.3	32.2	12.8	26.4	17.7	38.7	-0.6	-1.1	11.9	96.1
Extraordinary gains			2.1		0.2		1.5		0.8		4.6
Extraordinary losses			0.7		0.3		2.5		8.1		11.6
Income before income taxes and minority interests		17.0	33.6	12.7	26.3	17.2	37.7	-4.7	-8.5	11.1	89.1
Income taxes			23.6		13.1		17.7		-0.2		54.3
Minority interests											
Net income		<-60.1>		<48.0>		<-27.9>		<->		<-30.2>	
		5.1	10.0	6.4	13.2	9.1	20.0	-4.6	-8.3	4.3	34.8

	FY2010					
	Q1		Q2		Q2 YTD	
Net sales	<2.1>		<-4.0>		<-1.0>	
	100.0	201.6	100.0	198.8	100.0	400.4
Cost of Sales	22.3	44.9	27.4	54.4	24.8	99.3
Selling, general and administrative expenses	56.3	113.5	61.0	121.2	58.6	234.7
Research and development expenses	20.0	40.3	21.9	43.5	20.9	83.8
Other expenses	36.3	73.2	39.1	77.7	37.7	150.9
Operating income	<44.0>		<-11.6>		<18.1>	
	21.5	43.3	11.7	23.2	16.6	66.4
Non-operating income		1.8		1.9		3.7
Non-operating expenses		1.7		2.0		3.7
Ordinary income	<-34.8>		<-12.6>		<13.4>	
	21.5	43.4	11.6	23.1	16.6	66.4
Extraordinary gains		0.8		3.8		4.6
Extraordinary losses		4.2		1.0		5.2
Income before income taxes and minority interests	19.8	40.0	13.0	25.9	16.4	65.8
Income taxes		17.7		7.5		25.2
Minority interests				0.0		0.0
Net income	<122.8>		<-39.4>		<75.4>	
	11.1	22.3	9.2	18.3	10.2	40.6

<Ranbaxy Group>

(Billions of yen)

		FY2009									
		Q1		Q2		Q3		Q4		Full Year	
Net sales		<0.0> 100.0	29.7	<0.0> 100.0	36.4	<0.0> 100.0	36.0	<15.1> 100.0	44.5	<279.5> 100.0	146.7
Cost of Sales		57.7	17.1	56.0	20.4	55.0	19.8	40.6	18.1	51.4	75.4
Selling, general and administrative expenses		48.4	14.4	45.6	16.6	40.6	14.6	43.4	19.3	44.3	64.9
	Research and development expenses	7.1	2.1	6.3	2.3	6.6	2.4	7.9	3.5	7.0	10.3
	Other expenses	41.3	12.3	39.3	14.3	34.0	12.2	35.5	15.8	37.2	54.6
Operating income		<0.0> -	-1.8	<0.0> -1.6	-0.6	<0.0> 4.4	1.6	<-> 16.0	7.1	<-> 4.3	6.3
Non-operating income			1.0		9.0		2.5		8.7		21.1
Non-operating expenses			22.7		-11.9		2.9		0.7		14.5
Ordinary income		<0.0> -	-23.5	<0.0> 55.5	20.2	<0.0> 3.2	1.2	<-> 34.0	15.1	<-> 8.9	13.0
Extraordinary gains			0.0		0.0		0.0		1.3		1.3
Extraordinary losses			0.0		0.0		0.0		0.1		0.1
Income before income taxes and minority interests		-	-23.5	55.6	20.2	3.2	1.1	36.8	16.4	9.7	14.2
Income taxes			-6.6		6.0		1.3		9.2		9.8
Minority interests			0.0		0.0		0.1		0.1		0.2
Net income		<0.0> -	-16.9	<0.0> 39.1	14.2	<0.0> -0.6	-0.2	<-> 16.0	7.1	<-> 2.9	4.2

	FY2010					
	Q1		Q2		Q2 YTD	
Net sales	<84.9>		<20.1>		<49.2>	
	100.0	54.9	100.0	43.8	100.0	98.7
Cost of Sales	35.0	19.2	45.8	20.0	39.8	39.2
Selling, general and administrative expenses	29.8	16.4	39.1	17.1	33.9	33.5
Research and development expenses	6.0	3.3	7.0	3.0	6.4	6.4
Other expenses	23.8	13.1	32.1	14.1	27.5	27.1
Operating income	<->		<->		<->	
	35.2	19.3	15.1	6.6	26.3	25.9
Non-operating income		10.0		-3.0		7.0
Non-operating expenses		1.1		2.7		3.8
Ordinary income	<->		<-95.4>		<->	
	51.5	28.3	2.1	0.9	29.6	29.2
Extraordinary gains		0.0		5.2		5.2
Extraordinary losses		0.7		0.1		0.7
Income before income taxes and minority interests	50.3	27.6	13.8	6.0	34.1	33.7
Income taxes		9.2		1.5		10.7
Minority interests		0.1		0.1		0.1
Net income	<->		<-68.3>		<->	
	33.4	18.4	10.3	4.5	23.2	22.9

<Inter-Segment Transactions>

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Net sales					
Cost of Sales					
Selling, general and administrative expenses	1.5	1.5	1.5	1.5	6.0
Research and development expenses					
Other expenses	1.5	1.5	1.5	1.5	6.0
Operating income	-1.5	-1.5	-1.5	-1.5	-6.0
Non-operating income					
Non-operating expenses					
Ordinary income	-1.5	-1.5	-1.5	-1.5	-6.0
Extraordinary gains					
Extraordinary losses					
Income before income taxes and minority interests	-1.5	-1.5	-1.5	-1.5	-6.0
Income taxes	7.0	-6.4	-3.0	-11.8	-14.1
Minority interests	-8.9	7.1	0.7	6.5	5.3
Net income	0.5	-2.3	0.8	3.8	2.8

FY2010		
Q1	Q2	Q2 YTD
-0.1	-0.1	-0.2
0.0	0.0	0.0
1.5	0.7	2.1
0.0	-0.8	-0.9
1.5	1.5	3.0
-1.5	-0.7	-2.3
0.0	-0.7	-0.7
0.0	0.1	0.1
-1.5	-1.5	-3.0
0.0	-2.2	-2.2
0.0	0.2	0.2
-1.5	-3.9	-5.4
-0.3	-0.8	-1.2
6.4	0.7	7.1
-7.6	-3.8	-11.4

2. Currency Rate

	FY2009			
	Q1	Q2 YTD	Q3 YTD	Full Year
USD / Yen (average)	97.3	95.5	93.5	92.9
EUR / Yen (average)	132.6	133.2	133.0	131.2
INR / Yen (average)	1.89	1.95	1.95	1.95

FY2010	
Q1	Q2 YTD
92.0	89.0
117.0	113.8
1.98	2.01

3. Sales of Global Products

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Olmesartan <antihypertensive>	<10.5> 56.0	<10.2> 59.4	<12.3> 64.7	<19.0> 58.3	<12.9> 238.3
Olmetec (JPN)	<22.1> 19.0	<26.1> 19.8	<18.8> 22.2	<12.5> 16.2	<20.0> 77.2
Rezaltas (JPN)	-	-	-	-	-
Benicar / Benicar HCT (US)	<-5.6> 22.1	<0.5> 22.2	<2.0> 22.7	<11.7> 21.9	<1.8> 88.9
Azor (US)	<121.5> 3.0	<30.9> 3.2	<38.6> 3.6	<29.7> 2.9	<47.2> 12.8
Tribenzor (US)	-	-	-	-	-
Olmetec / Olmetec Plus (EU)	<-0.2> 8.3	<-3.7> 10.0	<12.1> 10.2	<17.7> 11.4	<6.5> 39.9
Sevikar (EU)	<-> 0.9	<-> 1.2	<56.5> 2.2	<156.5> 2.0	<189.3> 6.3
Other subsidiaries / Export, etc	<29.9> 2.6	<-7.8> 3.1	<6.2> 3.7	<71.4> 3.7	<19.2> 13.1
Levofloxacin <synthetic antibacterial>	<-23.2> 19.8	<-0.3> 23.5	<-14.2> 22.1	<-3.5> 21.8	<-10.7> 87.2
Cravit (JPN)	<-6.8> 9.5	<26.7> 11.9	<-21.0> 10.8	<17.5> 11.4	<1.5> 43.6
Export, etc	<-49.6> 4.8	<-22.7> 6.4	<-17.6> 5.1	<-29.5> 5.0	<-31.5> 21.3
Royalty	<-9.9> 3.7	<-19.3> 3.2	<0.7> 4.1	<-8.8> 3.6	<-9.3> 14.6
Other subsidiaries	<-6.4> 1.8	<2.9> 2.0	<14.7> 2.1	<-2.2> 1.8	<2.2> 7.7
Pravastatin <antihyperlipidemic>	<-8.5> 14.7	<-5.2> 15.0	<-10.8> 14.8	<-14.9> 10.5	<-9.6> 55.0
Mevalotin (JPN)	<-8.3> 12.4	<-5.0> 12.4	<-9.1> 12.8	<-14.7> 8.5	<-8.9> 46.2
Other subsidiaries / Export, etc.	<-10.0> 2.3	<-6.5> 2.6	<-20.2> 2.0	<-15.7> 2.0	<-12.8> 8.8

FY2010		
Q1	Q2	Q2 YTD
<7.6> 60.2	<3.4> 61.4	<5.4> 121.6
<8.7> 20.7	<6.5> 21.1	<7.6> 41.8
<-> 1.8	<-> 0.1	<-> 1.9
<-2.9> 21.4	<-6.8> 20.7	<-4.9> 42.1
<25.8> 3.8	<6.8> 3.4	<16.1> 7.2
-	<-> 0.7	<-> 0.7
<-4.2> 7.9	<-6.7> 9.3	<-5.6> 17.2
<84.9> 1.7	<97.4> 2.4	<92.0> 4.0
<7.7> 2.8	<25.4> 3.9	<17.3> 6.7
<-14.3> 17.0	<-28.0> 16.9	<-21.7> 33.9
<-18.3> 7.8	<-36.7> 7.5	<-28.5> 15.3
<-14.1> 4.1	<-29.8> 4.5	<-23.0> 8.6
<-18.9> 3.0	<-16.4> 2.7	<-17.7> 5.7
<15.8> 2.1	<10.6> 2.2	<13.0> 4.3
<-19.1> 11.9	<-21.5> 11.8	<-20.3> 23.7
<-17.9> 10.2	<-18.9> 10.1	<-18.4> 20.3
<-25.8> 1.7	<-34.1> 1.7	<-30.2> 3.4

Prasugrel (alliance revenue) <antiplatelet>	<-> 0.0	<-> 1.0	<-> 0.3	<-> -0.7	<-> 0.5
Effient (US)	<-> -	<-> 1.0	<-> 0.2	<-> -1.1	<-> 0.1
Effient (EU)	<-> 0.0	<-> 0.0	<-> 0.1	<-> 0.4	<-> 0.5

<-> 0.8	<-> 1.0	<-> 1.8
<-> 0.4	<-> 0.8	<-> 1.1
<-> 0.4	<-> 0.2	<-> 0.7

4. Overseas Sales

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Overseas sales	<23.9> 109.8	<42.6> 122.7	<43.9> 120.6	<12.6> 129.2	<29.2> 482.3
Overseas sales ratio	48.4%	50.4%	47.3%	57.0%	50.7%
North America	<1.1> 58.9	<16.6> 62.5	<11.5> 58.9	<18.1> 66.9	<11.7> 247.2
Europe	<21.3> 27.2	<27.6> 29.7	<32.9> 29.2	<3.0> 31.5	<19.7> 117.5
Other	<197.4> 23.7	<232.9> 30.5	<259.4> 32.5	<11.8> 30.8	<118.7> 117.6

FY2010		
Q1	Q2	Q2 YTD
<22.0> 134.0	<1.6> 124.7	<11.2> 258.6
52.2%	51.4%	51.8%
<31.7> 77.6	<8.4> 67.8	<19.7> 145.3
<12.4> 23.8	<12.6> 26.0	<12.5> 49.8
<37.4> 32.6	<1.3> 30.9	<17.1> 63.5

5. Geographic Segment Information

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Net Sales	<11.5> 227.1	<20.2> 243.4	<15.3> 255.1	<5.6> 226.4	<13.1> 952.1
Japan	<3.1> 128.5	<1.8> 135.4	<3.3> 146.4	<3.1> 109.2	<1.9> 519.4
North America	<7.0> 54.2	<20.4> 54.5	<15.6> 53.1	<24.1> 60.7	<16.6> 222.5
Europe	<48.1> 22.5	<32.4> 24.5	<37.8> 24.8	<6.7> 27.5	<28.2> 99.3
India	<-> 11.5	<-> 16.5	<-> 16.8	<-1.1> 15.1	<292.8> 59.9
Other	<99.7> 10.5	<115.3> 12.6	<136.2> 13.9	<17.5> 14.0	<76.4> 51.0
Operating Income	<-33.1> 26.8	<11.5> 24.1	<7.6> 39.2	<-> 5.4	<7.5> 95.5
Japan	15.6	11.9	22.9	-9.9	40.5
North America	13.9	13.0	12.4	7.7	47.1
Europe	1.2	1.9	3.1	3.0	9.1
India	-3.2	-1.7	3.1	6.3	4.5
Other	0.9	0.5	2.2	-0.2	3.3

FY2010		
Q1	Q2	Q2 YTD
<12.9> 256.4	<-0.4> 242.5	<6.0> 498.9
<3.1> 132.5	<-5.8> 127.6	<-1.4> 260.1
<33.2> 72.2	<15.3> 62.8	<24.3> 135.1
<-8.1> 20.6	<-7.9> 22.5	<-8.0> 43.2
<67.9> 19.3	<-2.2> 16.1	<26.5> 35.4
<12.1> 11.7	<6.3> 13.4	<8.9> 25.1
<128.1> 61.1	<20.6> 29.0	<77.2> 90.1
35.0	13.9	48.9
16.0	7.3	23.4
2.1	2.5	4.7
15.2	0.5	15.6
1.0	0.9	1.9

6. Status of Major Companies

Data available at www.daiichisankyo.com/ir/financial/index.html

6-1. Daiichi Sankyo Co., Ltd.

(Billions of yen)

	FY2009					FY2010		
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q2 YTD
Total net sales of ethical pharmaceuticals	<3.7> 104.6	<5.3> 104.8	<-1.4> 118.4	<-1.9> 84.5	<1.4> 412.3	<0.6> 105.3	<-1.7> 103.0	<-0.5> 208.3
Olmetec <antihypertensive>	<22.1> 19.0	<26.1> 19.8	<18.8> 22.2	<12.5> 16.2	<20.0> 77.2	<8.7> 20.7	<6.5> 21.1	<7.6> 41.8
Rezaltas <antihypertensive>	-	-	-	-	-	<-> 1.8	<-> 0.1	<-> 1.9
Calblock <antihypertensive>	<14.5> 3.5	<18.9> 3.5	<12.5> 3.8	<4.7> 2.9	<12.8> 13.7	<6.5> 3.7	<0.6> 3.5	<3.5> 7.2
Artist <antihypertensive>	<6.3> 6.0	<11.3> 5.9	<6.0> 6.4	<1.9> 5.0	<6.5> 23.3	<1.8> 6.1	<-1.6> 5.8	<0.1> 12.0
Mevalotin <antihyperlipidemic agent>	<-8.3> 12.4	<-5.0> 12.4	<-9.1> 12.8	<-14.7> 8.5	<-8.9> 46.2	<-17.9> 10.2	<-18.9> 10.1	<-18.4> 20.3
Kremezin <treatment for chronic renal failure>	<5.5> 3.4	<8.8> 3.5	<4.3> 3.7	<-0.5> 2.8	<4.7> 13.3	<5.5> 3.5	<-0.9> 3.5	<2.2> 7.0
Hanp <treatment for acute cardiac failure>	<1.5> 2.4	<11.3> 2.1	<-4.8> 2.6	<7.5> 2.3	<3.0> 9.4	<-0.2> 2.4	<-8.4> 1.9	<-3.9> 4.3
Livalo <antihyperlipidemic agent>	<22.8> 1.8	<25.9> 1.8	<18.8> 2.1	<10.5> 1.6	<19.6> 7.3	<9.9> 2.0	<7.9> 2.0	<8.9> 4.0
Sunrhythm <antiarrhythmic agent>	<-1.2> 3.0	<3.4> 3.0	<-0.8> 3.2	<-7.5> 2.3	<-1.3> 11.5	<-5.0> 2.9	<-9.5> 2.7	<-7.2> 5.6
Fastic <antidiabetic agent>	<1.8> 1.4	<7.3> 1.4	<-0.1> 1.4	<-6.4> 1.0	<0.9> 5.2	<-3.8> 1.3	<-9.4> 1.3	<-6.6> 2.6
Cravit <synthetic antibacterial agent>	<-6.8> 9.5	<26.7> 11.9	<-21.0> 10.8	<17.5> 11.4	<1.5> 43.6	<-18.3> 7.8	<-36.7> 7.5	<-28.5> 15.3
Loxonin <anti-inflammatory analgesic>	<33.0> 11.2	<19.7> 12.5	<16.0> 13.3	<19.4> 9.9	<21.4> 47.0	<15.9> 13.0	<11.0> 13.9	<13.3> 26.9
Urief <treatment for dysuria>	<26.6> 2.2	<26.1> 2.2	<19.3> 2.6	<-9.9> 2.0	<14.3> 9.0	<11.2> 2.5	<9.2> 2.5	<10.2> 4.9
Zyrtec <antiallergic agent>	<18.4> 2.4	<13.3> 1.8	<8.8> 2.4	<-15.1> 3.0	<2.7> 9.6	<-14.3> 2.1	<-0.9> 1.8	<-8.6> 3.8
Omnipaque <contrast agent>	<-2.0> 7.1	<3.4> 7.5	<-10.8> 7.1	<-4.8> 5.5	<-3.7> 27.3	<-10.1> 6.4	<-12.4> 6.6	<-11.3> 13.0

6-2. Daiichi Sankyo Healthcare Co., Ltd

(Billions of yen)

	FY2009					FY2010		
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q2 YTD
Daiichi Sankyo Healthcare Co., Ltd	<-6.9> 9.5	<-2.1> 13.5	<-8.2> 12.1	<-14.1> 8.6	<-7.4> 43.7	<-2.7> 9.3	<-12.9> 11.7	<-8.6> 21.0
LuLu Series	<-2.4> 1.2	<18.9> 4.3	<-19.5> 2.8	<12.8> 1.6	<1.5> 9.9	<37.0> 1.7	<-18.9> 3.5	<-6.6> 5.2
Gaster 10	<-29.1> 0.5	<-45.7> 0.5	<-38.9> 0.6	<-31.1> 0.5	<-37.0> 2.1	<-8.5> 0.5	<2.5> 0.5	<-3.1> 1.0
Daiichi Sankyo Ichoyaku series	<26.3> 0.9	<-1.1> 0.9	<2.8> 1.0	<7.9> 0.8	<7.8> 3.5	<-6.9> 0.8	<-13.4> 0.8	<-10.2> 1.6
Patecs series	<15.3> 0.9	<-17.8> 0.6	<-25.9> 0.5	<-11.6> 0.4	<-9.3> 2.4	<-37.0> 0.6	<-1.3> 0.6	<-22.1> 1.2
Transino	<-62.3> 0.3	<-72.0> 0.2	<37.4> 0.2	<96.4> 0.3	<-39.9> 0.9	<-13.4> 0.2	<-1.7> 0.1	<-9.1> 0.4

6-3. Daiichi Sankyo, Inc. (US)

(Billions of yen)

	FY2009					FY2010		
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q2 YTD
Daiichi Sankyo, Inc. (DSI)	<-11.2> 33.0	<5.6> 33.5	<5.8> 34.4	<15.2> 32.1	<2.9> 133.0	<1.7> 33.6	<1.2> 33.9	<1.5> 67.5
mil USD	<-4.6> 33.9	<21.7> 35.7	<13.4> 38.2	<18.0> 35.4	<11.4> 143.3	<7.6> 36.5	<10.2> 39.4	<8.9> 75.9
Benicar / Benicar HCT <antihypertensive>	<-5.6> 22.1	<0.5> 22.2	<2.0> 22.7	<11.7> 21.9	<1.8> 88.9	<-2.9> 21.4	<-6.8> 20.7	<-4.9> 42.1
mil USD	<1.4> 22.7	<15.6> 23.7	<9.7> 25.3	<14.8> 24.2	<10.2> 95.8	<2.7> 23.3	<1.6> 24.1	<2.1> 47.4
Azor <antihypertensive>	<121.5> 3.0	<30.9> 3.2	<38.6> 3.6	<29.7> 2.9	<47.2> 12.8	<25.8> 3.8	<6.8> 3.4	<16.1> 7.2
mil USD	<138.0> 3.1	<49.3> 3.4	<50.9> 4.0	<35.4> 3.2	<59.4> 13.8	<33.1> 4.2	<16.9> 3.9	<24.7> 8.1
Tribenzor <antihypertensive>	-	-	-	-	-	-	<-> 0.7	<-> 0.7
mil USD	-	-	-	-	-	-	<-> 0.7	<-> 0.7
Welchol <antihyperlipidemic / type 2 diabetes>	<7.0> 6.9	<6.6> 6.5	<10.2> 7.3	<28.2> 6.8	<12.4> 27.5	<1.8> 7.0	<13.4> 7.4	<7.4> 14.4
mil USD	<14.9> 7.1	<22.8> 6.9	<18.7> 8.1	<31.4> 7.5	<21.7> 29.6	<7.6> 7.6	<23.1> 8.5	<15.3> 16.2
Effient (alliance revenue) <antiplatelet>	-	<-> 1.0	<-> 0.2	<-> -1.1	<-> 0.1	<-> 0.4	<-> 0.8	<-> 1.1
mil USD	-	<-> 1.0	<-> 0.2	<-> -1.1	<-> 0.1	<-> 0.4	<-> 0.9	<-> 1.3

6-4. Luitpold Pharmaceuticals, Inc. (US)

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Luitpold Pharmaceuticals, Inc. (LPI)	<-1.1>	<-0.4>	<-6.4>	<18.9>	<1.9>
mil USD	13.4	13.5	12.6	12.7	52.1
	<6.2>	<14.5>	<1.1>	<21.4>	<10.3>
	13.7	14.4	14.0	14.0	56.1
Venofer	<-3.9>	<-4.6>	<-4.1>	<17.0>	<0.3>
<treatment for iron deficiency anemia>	8.0	8.1	8.0	8.0	32.2
mil USD	<3.2>	<9.6>	<3.3>	<19.8>	<8.6>
	8.2	8.7	8.9	8.9	34.6

FY2010		
Q1	Q2	Q2 YTD
<10.4>	<1.3>	<5.8>
14.7	13.7	28.4
<16.7>	<10.6>	<13.6>
16.0	15.9	31.9
<5.2>	<-5.0>	<0.1>
8.4	7.7	16.1
<11.3>	<3.8>	<7.4>
9.2	9.0	18.1

6-5. Daiichi Sankyo Europe GmbH

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Daiichi Sankyo Europe GmbH (DSE)	<14.1>	<-0.4>	<6.1>	<9.7>	<7.1>
mil €	17.3	18.4	19.1	20.4	75.2
	<40.6>	<20.8>	<5.9>	<9.8>	<17.1>
	13.1	13.8	14.4	16.1	57.4
Olmetec / Olmetec Plus	<-0.2>	<-3.7>	<12.1>	<17.7>	<6.5>
<antihypertensive>	8.3	10.0	10.2	11.4	39.9
mil €	<23.0>	<16.7>	<10.6>	<17.2>	<16.5>
	6.3	7.4	7.7	9.0	30.4
Sevikar	<->	<->	<56.5>	<156.5>	<189.3>
<antihypertensive>	0.9	1.2	2.2	2.0	6.3
mil €	<->	<->	<77.6>	<166.6>	<216.5>
	0.7	0.9	1.6	1.6	4.8
Evista	<-24.9>	<-27.5>	<-31.1>	<-4.6>	<-23.6>
<treatment for osteoporosis>	2.4	2.6	2.1	2.1	9.2
mil €	<-7.5>	<-12.2>	<-32.8>	<-10.1>	<-16.4>
	1.8	1.9	1.6	1.7	7.0

FY2010		
Q1	Q2	Q2 YTD
<-14.6>	<-10.0>	<-12.2>
14.8	16.6	31.4
<-3.2>	<8.3>	<2.7>
12.6	14.9	27.6
<-4.2>	<-6.7>	<-5.6>
7.9	9.3	17.2
<8.5>	<12.0>	<10.4>
6.8	8.3	15.1
<84.9>	<97.4>	<92.0>
1.7	2.4	4.0
<109.5>	<136.0>	<124.6>
1.4	2.1	3.6
<-29.6>	<-36.8>	<-33.3>
1.7	1.6	3.3
<-20.2>	<-23.6>	<-22.0>
1.5	1.5	2.9

Alliance Revenue of Efient (Europe)

Efient	<->	<->	<->	<->	<->
<antiplatelet>					
mil USD	<->	0.0	0.0	0.1	0.4
	<->	<->	<->	<->	<->
	0.0	0.0	0.1	0.4	0.5

<->	<->	<->
0.4	0.2	0.7
<->	<->	<->
0.5	0.3	0.8

Alliance Revenue of Efient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include Alliance Revenue of Efient (Europe).

6-6. Asia, South and Central America (ASCA)

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
ASCA Total	<0.5>	<7.1>	<11.7>	<27.5>	<12.1>
	5.3	6.3	6.6	7.7	25.8
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<-4.3>	<7.6>	<3.1>	<1.4>	<2.0>
	1.0	1.1	1.1	0.9	4.1
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	<48.0>	<40.2>	<35.2>	<34.0>	<38.4>
	1.1	1.3	1.4	1.5	5.3
Daiichi Sankyo Taiwan Ltd. (DSTW)	<-8.6>	<-14.9>	<-14.4>	<-4.5>	<-10.7>
	0.9	0.8	0.7	0.7	3.1
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<-15.6>	<-2.1>	<56.8>	<38.9>	<13.7>
	0.8	0.9	0.9	0.9	3.4
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<-0.9>	<-0.4>	<4.2>	<27.4>	<7.7>
	0.2	0.2	0.2	0.3	0.9
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	<-25.5>	<-12.7>	<-7.2>	<18.4>	<-5.2>
	0.8	1.0	1.3	1.6	4.7
Daiichi Sankyo Venezuela, S.A. (DSVE)	<35.3>	<45.0>	<20.7>	<76.3>	<47.9>
	0.7	0.9	0.8	1.7	4.1

FY2010		
Q1	Q2	Q2 YTD
<12.7>	<12.8>	<12.7>
5.9	7.1	13.0
<17.8>	<3.6>	<10.3>
1.1	1.1	2.2
<35.5>	<32.5>	<33.9>
1.4	1.7	3.2
<-8.6>	<1.0>	<-3.9>
0.8	0.8	1.6
<31.4>	<2.9>	<16.1>
1.0	0.9	1.9
<35.8>	<22.8>	<28.2>
0.2	0.3	0.5
<36.5>	<39.5>	<38.3>
1.0	1.4	2.5
<-46.7>	<-18.7>	<-31.0>
0.4	0.7	1.1

6-7. Ranbaxy Laboratories Limited

(Billions of yen)

	FY2009				
	Q1	Q2	Q3	Q4	Full Year
Ranbaxy Laboratories Limited (RLL)	<->	<->	<->	<14.9>	<279.3>
	29.7	36.4	36.0	44.4	146.6

FY2010		
Q1	Q2	Q2 YTD
<84.7>	<19.9>	<49.0>
54.8	43.7	98.5

(This page is intentionally left blank)

